SlidesetOncologyDrug-Drug Interactions between Small Molecule Inhibitors with Directly-Acting Oral Anti-coagulants (DOACs) in Patients with Lung Cancer. | Lorenz Van der Linden, PharmD, PhDView Slideset
SlidesetOncologyTherapeutic Drug Monitoring of Small Molecule Inhibitors in Patient with Lung Cancer: Ready for the Clinic? | Markus Jörger, MD, PhD, ClinPharmView Slideset
SlidesetOncologyManagement of Toxicities from Immunotherapy: an ESMO Clinical Practice Guideline | Caroline O'Leary, BA (Hons), MSc (LSE), MB BCh BAO (Hons), MRCPIView Slideset
